LLY vs BMY
By Alex · Tickerpine
Eli Lilly and Company vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | BMY |
|---|---|---|
| Price | $1,208.12 | $57.52 |
| Market cap | $1.08T | $117.46B |
| P/E ratio | 42.9 | 16.1 |
| ROE | 107.46% | 38.73% |
| Profit margin | 34.99% | 15.01% |
| Revenue growth | 55.50% | 2.60% |
| Dividend yield | 0.57% | 4.38% |
| Beta | 0.52 | 0.24 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs BMY in plain English
- LLY is the bigger company — about 9.2× the market cap of BMY.
- BMY is cheaper on earnings (P/E 16.1 vs 42.9).
- LLY earns a higher return on equity (107% vs 39%).
- LLY is growing revenue faster (56% vs 3%).
- BMY has the higher dividend yield (4.38% vs 0.57%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.